Search company, investor...

Predict your next investment

Venture Capital
braintrustvc.com

Investments

14

Portfolio Exits

2

Funds

2

About Brain Trust Accelerator Fund

The Brain Trust Accelerator Fund focuses on early stage investments that address the diagnosis and treatment of brain related diseases.

Headquarters Location

800 Airport Boulevard

Burlingame, California, 94010-1930,

United States

650-375-0200

Want to inform investors similar to Brain Trust Accelerator Fund about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Brain Trust Accelerator Fund News

NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II

Sep 23, 2020

Investment will allow NeuroTherapia to develop orally-available treatment for neurodegenerative disease. CLEVELAND, September 22, 2020-- NeuroTherapia, Inc., a clinical-stage company focused on developing therapies for neurodegenerative diseases, announced today the closing of its Series A financing of $8.8M. The Series A round, led by Brain Trust Accelerator Fund II, included investments from The Cleveland Clinic Foundation, Dolby Family Ventures and Alzheimer's Drug Discovery Foundation. NeuroTherapia is developing an orally available cannabinoid receptor agonist, NTRX-07, for the treatment of neuroinflammation, which likely plays a critical role in the progression of neurodegenerative diseases. "We were particularly attracted to this novel strategy for inhibiting neuroinflammation," commented John Reher, managing director of Brain Trust and lead investor in this financing. "We believe that inhibiting neuroinflammation may be beneficial not only for treating neurodegenerative diseases but could also be an important strategy for treating other brain disorders such as glioblastoma." Coincident with the financing, the company welcomes Karoly Nikolich, Ph.D. to its Board of Directors. Dr. Nikolich is an experienced scientist and entrepreneur, co-founding a number of biotech companies, and currently serving as CEO of Alkahest. He also led Genentech's entry into neuroscience and served as a venture partner with Pivotal BioVenture Partners. Dr. Nikolich joins Mr. Reher, who will serve as Chairman of the Board, Tony Giordano, Ph.D., NeuroTherapia's President and CEO, and Akhil Saklecha, M.D., from Cleveland Clinic on the Board. NeuroTherapia is currently completing its first-in-human clinical trial using NTRX-07 with funding provided in part by a grant from the Alzheimer's Association. The company will use the Series A funds to finish this work while also undertaking a number of preclinical studies. The additional studies are designed to support subsequent clinical trials in subjects with neurodegeneration to show safety following longer-term administration, as well as to demonstrate biological activity. "We are extremely fortunate to have this tremendous group of venture capitalists working with us," said Dr. Giordano. "Their expertise in developing molecules for brain disorders is greatly appreciated and I look forward to working with them in advancing NTRX-07 and our emerging pipeline of products." NeuroTherapia also recently received a $150,000 Technology Validation and Start-up Fund grant from the Ohio Third Frontier program of the Ohio Development Services Agency, which will allow the Company to complete additional research on the biodistribution of NTRX-07 following radiolabeling of the molecule. About NeuroTherapia NeuroTherapia, Inc. is a Cleveland-based biotech company developing a novel small molecule, NTRX-07, for the treatment of neurodegenerative disorders. NTRX-07 is a small orally-available molecule that targets receptors that are known to be increased in diseases including Alzheimer's disease (AD), ALS, MS and chronic pain syndromes. In various animal models of AD, NTRX-07 restored normal function of the microglia (key immune cells in the brain), which in turn decreased microglial-induced inflammation, reduced levels of the Alzheimer's associated Ab peptide in the brain, and substantially improved neuronal synaptic plasticity, learning, and memory. Additional information about NeuroTherapia can be found at www.neurotherapia.com.

Brain Trust Accelerator Fund Investments

14 Investments

Brain Trust Accelerator Fund has made 14 investments. Their latest investment was in Thirteen Lune as part of their Seed VC - II on January 1, 2023.

CBI Logo

Brain Trust Accelerator Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/19/2023

Seed VC - II

Thirteen Lune

$8M

Yes

Brain Trust Accelerator Fund, and Undisclosed Investors

1

9/22/2020

Series A

NeuroTherapia

$8.8M

Yes

4

8/28/2018

Series A - II

Chase Therapeutics

$4M

No

1

11/22/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/1/2015

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/19/2023

9/22/2020

8/28/2018

11/22/2017

3/1/2015

Round

Seed VC - II

Series A

Series A - II

Series A

Seed VC - II

Company

Thirteen Lune

NeuroTherapia

Chase Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$8M

$8.8M

$4M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Brain Trust Accelerator Fund, and Undisclosed Investors

Sources

1

4

1

10

0

Brain Trust Accelerator Fund Portfolio Exits

2 Portfolio Exits

Brain Trust Accelerator Fund has 2 portfolio exits. Their latest portfolio exit was Chase Pharmaceuticals on November 22, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/22/2016

Acquired

$99M

4

6/10/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

11/22/2016

6/10/2008

Exit

Acquired

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

4

0

Brain Trust Accelerator Fund Acquisitions

1 Acquisition

Brain Trust Accelerator Fund acquired 1 company. Their latest acquisition was Blue Buddha Beverages on December 23, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/23/2014

$99M

Acquired

1

Date

12/23/2014

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Brain Trust Accelerator Fund Fund History

2 Fund Histories

Brain Trust Accelerator Fund has 2 funds, including Brain Trust Accelerator Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/4/2017

Brain Trust Accelerator Fund II

Early-Stage Venture Capital

Open

$12.03M

2

12/31/2006

Brain Trust Accelerator Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/4/2017

12/31/2006

Fund

Brain Trust Accelerator Fund II

Brain Trust Accelerator Fund LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Open

Subscribe to see more

Amount

$12.03M

$99M

Sources

2

10

Brain Trust Accelerator Fund Team

1 Team Member

Brain Trust Accelerator Fund has 1 team member, including current Managing Director, John M. Reher.

Name

Work History

Title

Status

John M. Reher

Managing Director

Current

Name

John M. Reher

Work History

Title

Managing Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.